Skip to search formSkip to main contentSkip to account menu

HDAC-42

Known as: AR-42, HDAC Inhibitor AR-42, OSU-HDAC42 
An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, AR… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

Phenylbutyrates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.
AR-42 is a member of a novelly discovered class of phenylbutyrate-derived histone deacetylase inhibitors, and has a number of… 
2016
2016
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-4212
2016
2016
Association of downregulated HDAC 2 with the impaired mitochondrial function and cytokine secretion in the monocytes/macrophages from gestational diabetes mellitus patients
Gestational diabetes mellitus (GDM) is associated with an increased risk of type 2 diabetes (T2DM) and cardiovascular diseases in… 
2016
2016
AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition
Histone deacetylases (HDACs) play critical roles in apoptosis and contribute to the proliferation of cancer cells. AR-42 is a… 
2016
2016
A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.
2558Background: We have shown that AR-42, an oral pan-histone deacetylase inhibitor, has clinical activity in some hematologic… 
2014
2014
Abstract 5540: Preclinical investigation of the novel histone deacetylase (HDAC) inhibitor AR-42 in the treatment of cancer-induced cachexia
Background: Cachexia occurs in more than 50% of cancer patients. Cachexia is characterized by severe loss of weight and skeletal… 
2013
2013
An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA
Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their… 
2013
2013
Aberrant expression of CCR4 in diffuse large B-cell lymphoma, not otherwise specified
1 Strout MP, Marcucci G, Bloomfield CD, Caligiuri MA. The partial tandem duplication of ALL1 (MLL) is consistently generated by… 
2008
2008
Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
OBJECTIVE To determine whether exposure of canine cancer cells to histone deacetylase (HDAC) inhibitors S(+)-N-hydroxy-4-(3… 
2006
2006
Preclinical pharmacokinetic studies with s-HDAC-42 (NSC 736012), an inhibitor of histone deacetylase, by LC-MS/MS
3091 Purpose. R, S-HDAC-42 (NSC 731438), an inhibitor of histone deacetylase, has been found to possess potent cytotoxicity in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)